Related Experiment Video
Updated: Sep 18, 2025
Evaluation of Biomaterials for Bladder Augmentation using Cystometric Analyses in Various Rodent Models
Published on: August 9, 2012
Efficacy of Solifenacin, Mirabegron, and Combination Therapy in Children With Daytime Urinary Incontinence (BeDry):
Ann-Kristine Mandøe Svendsen1,2,3, Søren Hagstrøm4,5, Kristina Thorsteinsson4,5
1Department of Pediatrics and Adolescent Medicine, Gødstrup Hospital, Herning, Denmark.
Insights
This study evaluates combination therapy for childhood daytime urinary incontinence. It compares low-dose solifenacin and mirabegron combinations against high-dose monotherapy to optimize treatment and improve quality of life.
Area of Science:
- Pediatric Urology
- Clinical Pharmacology
Background:
- Standard urotherapy and anticholinergics are first-line treatments for pediatric daytime urinary incontinence.
- Evidence for medical treatment efficacy in children is limited, primarily from nonrandomized trials.
Purpose of the Study:
- To compare low-dose combination therapy (solifenacin/mirabegron) with high-dose monotherapy for daytime urinary incontinence in children aged 5-14 years.
- To assess treatment response, side effects, safety, tolerability, well-being, and quality of life.
Main Methods:
- Randomized trial with 4 arms for children refractory to standard urotherapy.
- Initial treatment with solifenacin 5 mg or mirabegron 25 mg for 6 weeks, followed by add-on therapy for non-responders.
- Total treatment duration of 18 weeks, with response measured by reduction in wet days using DryPie.
Main Results:
- The BeDry study (EUCT 2023-510187-13-00, NCT06551246) is currently recruiting patients.
- As of April 2025, 75 out of a planned 236 participants have been enrolled.
- Full results are pending completion of recruitment by September 2026.
Conclusions:
- This trial aims to optimize medical treatment for pediatric daytime urinary incontinence.
- Potential to shorten treatment duration, reduce side effects, and minimize healthcare costs.
- Findings could lead to improved management strategies and patient outcomes.
Background:
According to International Children's Continence Society, the first-line treatment of children with daytime urinary incontinence is standard urotherapy, eventually followed by pharmacotherapy of anticholinergics. The effect of medical treatment is sparsely investigated and has been investigated primarily in nonrandomized trials.
Objective:
The primary objective of this trial is to evaluate if (1) combination therapy of solifenacin and mirabegron in low doses is superior to monotherapy of solifenacin in high dose and if (2) combination therapy of mirabegron and solifenacin in low doses is superior to monotherapy of mirabegron in high dose in the treatment of daytime urinary incontinence among children aged 5-14 years who are noncomplete responders to monotherapy of solifenacin in low dose or monotherapy of mirabegron in low dose. The secondary objective is to evaluate the treatment response of combination therapy of solifenacin and mirabegron in low doses, monotherapy in high doses, and monotherapy in low doses as supplementary comparisons. Additionally, the secondary objective is to evaluate the side effects, safety, and tolerability of the medical treatment as well as the effect of the treatment on the well-being and quality of life.
Methods:
Children aged 5-14 years diagnosed with daytime urinary incontinence refractory to standard urotherapy will be randomized 1:1:1:1 to 4 treatment groups. Initially, 2 groups will receive solifenacin 5 mg and 2 groups will receive mirabegron 25 mg. After 6 weeks, noncomplete responders will receive add-on treatments according to their primary randomization group. Group 1A will receive solifenacin 5 mg and add-on solifenacin 5 mg, group 1B will receive solifenacin 5 mg and add-on mirabegron 25 mg, group 2A will receive mirabegron 25 mg and add-on mirabegron 25 mg, and group 2B will receive mirabegron 25 mg and add-on solifenacin 5 mg. The total treatment period will be 18 weeks. The primary end point measure is treatment response assessed by change from visit 2 to the end of the study, according to the number of wet days per 7 days by DryPie.
Results:
The BeDry study was approved by Clinical Trials in the European Union on June 12, 2024. Recruitment began on June 27, 2024, and will continue until 236 patients are included, which is expected to occur by September 2026. As of April 2025, 75 participants are included.
Conclusions:
This trial has the potential to optimize the medical treatment of children with daytime urinary incontinence, shorten the treatment period, diminish the side effects, and minimize unnecessary medical expenses.
Trial Registration:
Clinical Trials in the European Union EUCT 2023-510187-13-00; https://tinyurl.com/2hva7ph8; ClinicalTrials.gov NCT06551246; https://clinicaltrials.gov/study/NCT06551246.
International Registered Report Identifier (Irrid):
PRR1-10.2196/63588.
Related Concept Videos
01:26The Micturition Reflex
The process begins with bladder filling, where the bladder wall stretches as urine accumulates. This stretching activates the urine storage reflex, mediated by the sacral spinal segments and the pontine storage center. Efferent sympathetic impulses stimulate the detrusor muscle to relax and the internal urethral sphincter to contract, facilitating...
01:30Urinary Tract Infection III: Diagnostic Studies and Interprofessional Care
01:17Drugs for Treatment of Diarrhea-Predominant IBS
Two specific drugs used in the treatment are alosetron (Lotronex) and eluxadoline (Viberzi). Alosetron, a 5-HT3 antagonist, works by slowing the movement of stools in the gut, reducing bowel...
01:17Urinary Tract Infection IV: Nursing Management
01:30Urinary Tract Calculi III: Medical Management
01:19Urodynamic Studies: Uroflowmetry